Lineage Cell Revenue Doubles in Q2
Lineage Cell Therapeutics (NYSEMKT:LCTX), a biotechnology company advancing cell-based therapies for serious diseases, released its earnings for the quarter ended June 30, 2025 on August 12, 2025. The headline news from the release was a major revenue beat, as GAAP revenue of $2.8 million exceeded the analysts' estimate of $1.47 million, with Quarterly sales (GAAP) rose to $2.8 million—well above the analyst estimate of $1.47 million (GAAP). However, Earnings per share (GAAP) registered at $(0.13), a greater loss than the estimated $(0.03) (GAAP), due largely to non-recurring charges. Overall, while the company advanced clinically and operationally during the quarter, that progress was overshadowed in the results by substantial, one-time accounting items that led to an unusually high net loss.
Source: Analyst estimates for the quarter provided by FactSet.
Lineage Cell Therapeutics is focused on developing cell therapies aimed at addressing major medical conditions—especially eye disorders, spinal cord injuries, and hearing loss. Its pipeline is anchored by key programs that use specialized cells derived from its proprietary technology platform. This platform allows the company to design and manufacture precise human cells for therapeutic use.
Source Fool.com
